Autolus Stock Sinks 5% After Earnings — Its Multiple-Sclerosis Data Presentation Moves Further Out
AUCATZYL sales rose 95%, and Autolus expects annual sales to meet or exceed $150 million, the top of its previous forecast.
Autolus Therapeutics, which makes treatments that reprogram patients’ immune cells to target disease, fell 4.55% to $1.26 in Tuesday trading, as of 10:10 AM ET, erasing $16 million in market value on the day it reported third-quarter results. On the earnings call, Chief Executive Christian Itin said the early multiple-sclerosis findings were not actionable.
Longer Follow-Up For Multiple Sclerosis
Autolus pushed its data presentation for multiple sclerosis to October 2027, according to Tuesday’s results filing. Specialists recommended more follow-up, and the company expects at least 12 months of observation for the initial 12 patients.
Management also fielded questions on the call about competitors’ findings and its decisions on multiple-sclerosis development. The presentation delay puts a longer observation period between the early findings and the planned public readout.
AUCATZYL Sales Lift Annual Expectations
A 95% increase brought AUCATZYL’s third-quarter sales to $41.2 million. For Autolus, $150 million is now the annual sales floor rather than the forecast ceiling.
AUCATZYL treats adults whose B-cell precursor acute lymphoblastic leukemia has returned or resisted treatment. Autolus sells it in the United States and United Kingdom, where only authorized specialist centers can administer the therapy.
The company manufactures AUCATZYL at its Nucleus facility in Stevenage, U.K., and the treatment is available through the National Health Service in England and Wales. Its development work extends to other blood cancers, solid tumors and autoimmune diseases, including lupus and multiple sclerosis.
A Slide Despite Growing Sales
Autolus entered Tuesday down 34% for the year through Monday’s close, while the S&P 500 had gained 10%. Its shares had also lost 27% over the previous month.
In Tuesday trading, as of 10:10 AM ET, the stock was on pace for its third drop of 3% or more this month, and the company’s market value stood at about $335 million.
The company’s second-quarter results paired $45.7 million in revenue, up 118.4% from a year earlier, with a $39.1 million net loss. Growing sales and continuing losses were already part of the backdrop to Tuesday’s report.
Itin is scheduled to present next Tuesday at the Jefferies Global Healthcare Conference in London.
Sources
- Autolus Therapeutics Q3 2026 Earnings Call Transcript — benzinga.com
- Autolus Therapeutics GAAP EPS of -$0.21 misses by $0.03, revenue of $41.24M beats by $1.21M (AUTL:NASDAQ) | Seeking Alpha — seekingalpha.com
- Autolus Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- Autolus Therapeutics to Participate in the Jefferies Global — globenewswire.com
- The company's filing (Autolus Therapeutics) — SEC filing
- Autolus Therapeutics — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR
